Hims & Hers Health, Inc.

02 Executive Summary

Hims & Hers entered 2026 as one of the most compelling growth stories in digital health — a company that scaled from $527M in FY22 revenue to $2.35B in FY25, achieving GAAP profitability along the way. That narrative is now under material stress: a Q1 2026 EPS miss of -1,664% vs. consensus, an FTC lawsuit alleging illegal health data sharing and deceptive billing practices, and Argus Research cutting its price target three times in as many weeks signal a new risk regime.^{[S9][S10][S14]}

Top Catalysts:

• Q2 2026 earnings (August 10): Revenue consensus of $719.2M implies +32.0% YoY growth vs. Q2 2025's $544.8M — a beat-and-raise would re-establish execution credibility.
• FTC litigation resolution: A settlement or dismissal removes the single largest overhang on valuation multiple expansion and removes regulatory execution risk.
• FY27 profitability inflection: Street consensus projects EPS recovering to $0.62 in FY27 vs. a loss year in FY26, implying meaningful operating leverage if revenue scales to $3.9B.

Key Risks:

• FTC lawsuit escalation: Alleged sharing of patient health data with Meta and Snap advertisers could trigger HIPAA-adjacent penalties, injunctive relief, and lasting brand damage.^[S10][S11]
• GLP-1 compounding window closing: FDA enforcement actions on compounded semaglutide could eliminate a material revenue stream with limited advance notice.
• Q1 2026 EPS collapse (-$0.40 actual vs. +$0.026E): Underlying cost structure deterioration, with operating income swinging to -$78.3M from +$57.9M in Q1 2025, suggests margin discipline has broken down temporarily or structurally.

At 21.3x forward P/E on FY26E EPS of -$0.13 (loss year), the forward multiple is unanchored. The stock trades at 2.87x EV/Revenue and 81.6x EV/EBITDA on TTM figures — premium pricing for a business now generating a -7.9% operating margin on a TTM basis. We rate HIMS HOLD with a $30.00 price target, blending a DCF base case with NTM EV/Revenue. Upside requires the FTC headwind to dissipate and Q2 2026 to demonstrate a return to margin expansion.

03 Financial Performance & Health

3a. Income Statement Analysis

HIMS compounded revenue at 63.5% annually from FY22 to FY25, scaling from $526.9M to $2.35B — an extraordinary growth trajectory for a telehealth platform. Gross margins held remarkably stable in the 73-79% range, reflecting the inherent leverage in the subscription-based digital model. However, Q1 2026 marked a stark inflection: operating income cratered to -$78.3M from +$57.9M in Q1 2025, a $136.2M YoY swing, driven by what appears to be a significant step-up in marketing and/or infrastructure spend tied to new product launches and GLP-1 compounding operations.

The TTM revenue growth rate has decelerated sharply to just +3.8% YoY on a trailing basis, a significant come-down from the 59% YoY growth HIMS posted in FY25. This reflects base effects from the explosive 2025 GLP-1 compounding ramp and is expected to normalize as Q2-Q4 2026 comps roll in.

• FY25 revenue of $2.35B grew +58.9% YoY from FY24's $1.48B.
• FY25 gross margin of 73.8% vs. 79.4% in FY24 — compression driven by product mix shift toward lower-margin compounded GLP-1 formulations.
• FY25 operating income of $105.6M represented first full year of sustained operating profitability.
• Q1 2026 operating loss of -$78.3M reversed all of FY25's operating income gains in a single quarter.
• TTM net income of approximately -$13.2M (estimated from quarterly data) reflects the Q1 2026 collapse overwhelming prior profitability.

Note: TTM figures estimated by summing Q2 2025 through Q1 2026 quarterly data from locked facts. Gross profit TTM estimated from available quarterly data.

3b. Balance Sheet Analysis

The FY25 balance sheet reflects a major structural transformation — total debt surged from $11.3M at end-FY24 to $1.12B at end-FY25, a near-100x increase. This appears tied to debt raised to fund pharmacy infrastructure, compounding operations, and potentially M&A. Total assets grew from $707.5M to $2.15B over the same period, suggesting significant capital deployment into fixed assets or goodwill. The equity base of $540.9M looks thin relative to $1.12B in debt.

• Net debt moved from a net cash position of approximately $209.2M at end-FY24 to net debt of $891.9M at end-FY25.
• Total liabilities grew $1.38B YoY — from $230.8M to $1.61B — in a single fiscal year.
• Cash on hand of $228.6M provides approximately 8 months of operating cash burn at the Q1 2026 run rate.
• Current ratio and debt-to-equity ratios are unavailable from locked data for granular current/non-current splits; net debt/EBITDA is estimated below.

Note: Current ratio not calculable from available locked data as current/non-current asset and liability splits were not provided. Net debt calculated as total debt minus cash.

TTM EBITDA is estimated at approximately $83.4M (EV of $6.81B ÷ EV/EBITDA of 81.6x). At that level, net debt/EBITDA of approximately 10.7x is elevated and warrants monitoring — though the FCF profile ($174.3M TTM) is considerably stronger than reported EBITDA suggests, as D&A and stock-based compensation add back meaningfully.

3c. Cash Flow Analysis

HIMS's operating cash flow has grown consistently, expanding from -$26.5M in FY22 to $300.0M in FY25. However, capital expenditures escalated dramatically in FY25 to $242.6M — nearly 5x the FY24 CapEx of $52.8M — compressing FCF from $198.3M in FY24 to just $57.4M in FY25. This CapEx spike reflects the build-out of compounding pharmacy infrastructure and is the primary driver of the FY25 FCF miss vs. what operating cash flow alone would imply.

• FY25 CapEx as % of revenue: 10.3% vs. 3.6% in FY24 — a significant step-up in capital intensity.
• TTM FCF of $174.3M benefits from Q1 2026's positive FCF of $53.0M and Q3 2025's $79.4M.
• Q2 2025 FCF was -$69.4M (OCF -$19.1M, CapEx -$50.3M), showing quarterly volatility.
• FY26E CapEx trajectory is a critical unknown — if normalized below $150M annually, FCF recovers significantly.

Note: TTM OCF and CapEx estimated by summing Q2 2025 through Q1 2026 quarterly figures from locked data. FCF per share estimated using ~231M shares outstanding (est.). FY2021 cash flow data was not available in locked facts and has been omitted.

3d. Return on Capital

HIMS generated its first meaningful positive returns on capital in FY24 and FY25, but the Q1 2026 collapse has temporarily reversed the trajectory on a TTM basis. The FY25 net income of $128.4M on average equity of approximately $509M yields ROE of approximately 25.2%. However, the newly debt-laden balance sheet distorts ROE interpretation — ROIC, which adjusts for the capital structure, is a more meaningful metric here.

• FY25 ROE (est.): approximately 25.2% — flattered by high financial leverage relative to historical periods.
• FY24 ROE (est.): approximately 29.7% — peak profitability year on lean balance sheet.
• TTM ROIC (est.): approximately 5.2% — depressed by Q1 2026 losses and the $1.12B debt addition.
• Cost of capital estimated at 10-11% (est.) — meaning HIMS is currently destroying economic value on a TTM basis.

All return metrics for FY2023–FY2025 and TTM are estimated using average balance sheet figures and available income data from locked facts. ROIC estimated as NOPAT divided by average invested capital.

04 Valuation

4a. Multiples Analysis

HIMS trades at significant premiums to most traditional healthcare and telehealth comps on EV/EBITDA and EV/Revenue, justified historically by its superior growth rate. With TTM revenue growth decelerating to 3.8% (a base-effect anomaly) and TTM operating margins negative, the premium is increasingly difficult to defend in the near term. The forward P/E of 21.3x is nominal on a loss year (FY26E EPS of -$0.13), making it a misleading anchor for valuation purposes.

• HIMS trades at 2.87x EV/Revenue vs. peers typically at 1-3x — roughly in-line, but peers are generally profitable.
• EV/EBITDA of 81.6x reflects a thin EBITDA base, not a permanently stretched multiple.
• P/B of 14.4x reflects the asset-light, high-growth nature of the core business — not unreasonable if growth re-accelerates.
• 52-week range of $13.74-$65.59 illustrates the extreme sentiment swings in HIMS — the stock has traded at a 4.8x range in one year.

Competitor figures are estimates as of July 2026 using publicly available data where accessible. Roman Health is a private company; metrics not available. TDOC and LFMD estimates are sourced from analyst memory and marked accordingly.

4b. Discounted Cash Flow (DCF) Analysis

Our DCF anchors on FY26E consensus revenue of $3.0B and assumes a gradual operating margin recovery from the Q1 2026 trough. Key assumptions: revenue growth guided by analyst consensus through FY27E at $3.9B, then normalizing to 18% in FY28, 14% in FY29, and 10% in FY30. Operating margins assumed to recover from -3% in FY26E to +8% by FY28E and +12% by FY30E as GLP-1 infrastructure CapEx normalizes and fixed cost leverage kicks in.

• WACC: 10.5% (beta approximately 1.8 est., risk-free rate 4.4%, equity risk premium 5.5%)
• Terminal growth rate: 3.0% (base case), reflecting long-run telehealth market growth
• CapEx as % of revenue: Normalizing from 10% in FY26E to 4% by FY28E+
• Tax rate: 25% assumed from FY27 onward as profitability stabilizes
• Shares outstanding: ~231M (est., diluted)

4c. Valuation Conclusion

At $27.77, HIMS is roughly fairly priced relative to our base-case DCF of $30.00, offering limited margin of safety given current execution uncertainty. The bear case at $14.00 is uncomfortably close to the 52-week low of $13.74 — suggesting the market already partially discounts a severe downside scenario but has not fully priced it out.

• Our $30.00 target blends 60% DCF base case ($30) and 40% NTM EV/Revenue of 2.5x applied to FY27E revenue of $3.9B, implying a market cap of approximately $30 per share.
• Margin of safety at current price is thin at approximately 8% — consistent with a HOLD, not a BUY.
• The stock needs the FTC litigation to resolve favorably AND Q2 2026 earnings to demonstrate margin recovery before the multiple can sustainably expand.

05 Business Model & Competitive Moat

5a. Business Segments

HIMS operates a direct-to-consumer telehealth and pharmacy platform with a subscription-first business model. The company connects patients with licensed providers, then fulfills prescriptions through its affiliated pharmacy network — including proprietary compounding facilities built out aggressively in FY25. Revenue is generated primarily through recurring subscription fees rather than episodic transactions, which drives the high gross margin profile.

The platform has historically been anchored in men's sexual health (erectile dysfunction, hair loss) and women's wellness (contraception, menopause). The GLP-1 weight management category, added in 2023-2024, has become the fastest-growing segment, though the compounding model faces acute regulatory risk. HIMS does not publicly break out revenue by segment with granularity, so the table below uses available estimates.

• Men's health (ED, hair loss): estimated 35-40% of FY25 revenue, mature growth, high-margin anchor (est.).
• Weight management (GLP-1 compounding): estimated 30-35% of FY25 revenue, hypergrowth but regulatory risk (est.).
• Women's health and dermatology: estimated 20-25% of FY25 revenue, steady growth (est.).
• Mental health, primary care, and other: estimated 5-10% of FY25 revenue (est.).

Segment revenue estimates are analyst estimates based on available public disclosures and management commentary. HIMS does not report fully disaggregated segment financials. All figures marked as estimated.

5b. Economic Moat Assessment

HIMS's moat profile is narrower than its growth trajectory implies. Morningstar has characterized the company as having "no moat," a view consistent with the competitive entry seen in men's health telehealth from Roman, Keeps, and GoodRx.^[S12] The strongest moat sources are brand recognition among a specific demographic and modest switching costs embedded in subscription relationships. Neither is durable against a well-capitalized challenger.

• Brand is HIMS's most defensible asset — but it is now under active threat from FTC litigation alleging consumer deception.^[S11]
• The proprietary compounding pharmacy infrastructure represents a cost advantage in the GLP-1 segment — but only as long as the regulatory window remains open.
• Network effects are limited: the platform does not benefit from user-to-user value creation the way marketplace businesses do.

Overall Moat Assessment: Narrow. HIMS has a recognizable consumer brand and operational scale advantages in fulfillment, but these advantages are not structurally defensible against a larger healthcare platform or a major pharmaceutical company entering direct-to-consumer telehealth. The "no moat" designation from at least one major analyst house reflects the genuine competitive vulnerability.^[S7]

06 Growth Strategy & Future Outlook

6a. Growth Drivers

HIMS's growth algorithm across all time horizons depends on two core variables: subscriber growth and ARPU expansion through product diversification. The near-term narrative is dominated by GLP-1 execution and FTC litigation resolution. Medium-term upside comes from women's health, mental health, and international expansion. Long-term optionality includes personalized medicine, data-driven diagnostics, and potential pharmacy benefit manager (PBM) disruption plays.

Near-Term Catalysts (0-12 months):

• Q2 2026 earnings (August 10): Street consensus of $719.2M revenue (+32% YoY) and EPS of -$0.05. A beat on both lines would materially re-rate the stock.^[S2]
• FTC lawsuit trajectory: A settlement announcement or preliminary injunction ruling is the single highest-impact near-term binary event.^[S9][S13]
• GLP-1 compounding regulatory clarity: FDA's ongoing review of compounded semaglutide shortage status; resolution either removes an overhang or creates a revenue gap.

Medium-Term Drivers (1-3 years):

• Women's health expansion: contraception, menopause, and fertility categories represent a largely untapped ARPU opportunity for the existing subscriber base.
• Mental health scale: psychiatry and therapy services have large TAM and recurring revenue characteristics similar to the core model.
• FY27E revenue consensus of $3.93B implies 30.9% YoY growth — requires successful new category penetration alongside core market expansion.

Long-Term Opportunities (3-5+ years):

• International telehealth expansion — the company has begun exploring UK and other English-speaking markets (est., based on prior mgmt commentary).
• Diagnostic and genomics integration: personalized treatment protocols using genetic data could differentiate HIMS from commoditized telehealth platforms.
• Pharmacy benefit disruption: HIMS's direct pharmacy model positions it to disintermediate traditional PBMs for a narrow set of chronic conditions.

6b. Total Addressable Market (TAM)

The total addressable market for HIMS's core categories is large and underpenetrated. The U.S. telehealth market is estimated at $80-100B by 2030 (est., multiple industry sources), with HIMS currently capturing a fraction. More relevant is the condition-specific TAM — the obesity/GLP-1 market alone is projected at $100B+ by 2030 (est.), though HIMS's claim on that TAM through compounding is inherently transitional.

6c. Competitive Positioning

HIMS is the category leader in men's direct-to-consumer telehealth — a position it established through early brand investment and DTC marketing mastery. In the broader telehealth market, it is a challenger relative to Teladoc Health ($1.7B revenue est.), which has broader clinical scope and enterprise relationships. In the GLP-1 specific segment, HIMS has been more aggressive than any other DTC platform in building compounding infrastructure.

• Teladoc (TDOC): Larger scale, enterprise-focused, but structurally unprofitable and losing subscribers. HIMS's DTC model has proven more resilient.
• LifeMD (LFMD): Direct competitor in men's health and weight management; much smaller scale ($250M revenue est.) but similar model — demonstrates the category is real, not winner-take-all.
• Amazon Pharmacy / One Medical: The latent threat — Amazon's distribution scale and Prime membership could disrupt HIMS's patient acquisition economics if it moves aggressively into telehealth prescribing.

07 Management & Governance

7a. Leadership

Andrew Dudum has served as CEO and Co-Founder since the company's 2017 founding — giving him 9 years of tenure and providing continuity through the company's rapid scaling. His background is venture capital (Atomic Ventures), not traditional healthcare, which explains both HIMS's marketing-first DNA and its periodic regulatory friction. The FTC lawsuit is in part a consequence of growth-first product decisions that a more healthcare-native leadership team might have avoided.

• CEO — Andrew Dudum: Co-founder, 9 years tenure (est.). Track record of aggressive growth execution; now facing the first major governance/regulatory challenge of his tenure.
• CFO: Specific CFO name and background are not confirmed in the evidence pack; transcript evidence is unavailable for this report period. We note this limitation rather than assert unverified names.
• Board: Specific board composition details are not available in the current evidence pack; the July 2026 8-K filing related to corporate changes may reflect governance updates.^[S17][S18]

7b. Capital Allocation Track Record

Mgmt's capital allocation in FY25 was the most consequential in the company's history — and the most controversial. The decision to raise $1.12B in debt and deploy $242.6M in CapEx (up from $52.8M in FY24) to build proprietary compounding infrastructure was a high-conviction bet on the GLP-1 category. If the regulatory window remains open, this proves prescient. If the FDA closes compounding at scale, it is a capital allocation blunder of the first order.

• FY25 CapEx spike: $242.6M vs. $52.8M in FY24 — nearly all directed at pharmacy and compounding infrastructure (est.).
• Debt issuance: $1.12B total debt at FY25 year-end vs. $11.3M at FY24 — a deliberate leverage-up to fund the GLP-1 buildout.
• No dividends paid, no buybacks announced — all capital directed at growth reinvestment, which is appropriate for the growth stage.
• No significant M&A in the evidence pack's lookback window; growth has been primarily organic.

Capital Allocation Rating: Fair. The FY25 bet on compounding infrastructure was bold and tactically sound given the GLP-1 demand backdrop, but the leverage and CapEx intensity at a moment of regulatory uncertainty creates fragility. The jury is out pending FDA/FTC resolution.

7c. Insider Ownership & Alignment

Specific insider ownership percentages and recent insider transaction data are not available in the current evidence pack. The July 2026 SEC 8-K filing related to corporate changes and voting matters may contain relevant governance updates.^[S17][S18] Investors should review the most recent DEF 14A proxy filing directly for current ownership percentages and compensation structure. We note this data limitation rather than estimate.

• Co-founder CEO Dudum's equity stake at founding provides alignment with long-term value creation.
• Absence of buyback activity through periods of stock weakness (from the $65.59 high to current $27.77) suggests either capital constraints or confidence in reinvestment alternatives.
• The aggressive FY25 infrastructure buildout aligns mgmt incentives with revenue growth metrics, which may not fully align with shareholder return objectives in a down market for the stock.

08 Risk Analysis

8a. Company-Specific (Idiosyncratic) Risks

The FTC lawsuit is the dominant near-term risk and represents a genuinely novel threat to HIMS's business model — not just a regulatory fine, but potential operational restrictions on data practices that underpin the company's marketing engine.^[S10][S11] Alongside it, the GLP-1 compounding regulatory window and the Q1 2026 cost structure deterioration represent the other two most material company-specific risks.

• HIMS publicly disputes the FTC's characterization, asserting the agency "disregards substantial evidence."^[S13] A contested litigation path means uncertainty persists for 12-24 months minimum.
• The Q1 2026 operating loss of -$78.3M vs. Q1 2025 operating income of +$57.9M represents a $136.2M YoY swing that mgmt has not fully explained in available disclosures.
• Total debt of $1.12B at 2.07x D/E is an emerging credit concern if FCF generation deteriorates.

8b. Industry & Macro (Systemic) Risks

Telehealth faces a regulatory reset cycle as COVID-era prescribing flexibilities expire and DEA/FDA tighten controlled substance telehealth rules. HIMS's business straddles multiple regulatory jurisdictions — FDA (compounding), FTC (consumer protection), DEA (controlled substances), and state medical boards — creating an unusually complex compliance surface.

09 Final Recommendation

HIMS remains one of the most asymmetric stories in digital health — a platform with genuine scale ($2.35B FY25 revenue, 73% gross margins, $300M annual OCF) and a proven ability to identify and monetize underserved patient populations at consumer-friendly price points. The core thesis to own this stock is singular: that the FTC and FDA regulatory headwinds resolve without structurally impairing either the marketing engine or the GLP-1 revenue stream, enabling the business to recover to its FY25 profitability trajectory and grow into FY27E consensus of $3.93B. Until Q2 2026 earnings on August 10 provide that evidence, HOLD is the only intellectually honest rating.

10 Open Questions & Narrative Checkpoints

• Question: What specifically caused Q1 2026's -$78.3M operating loss vs. +$57.9M in Q1 2025 — is the $136.2M YoY swing structural (permanent cost base expansion) or transitory (one-time launch costs, inventory build, legal fees)? Why it matters: If structural, the FY26E consensus operating margin assumption and FY27E profitability recovery thesis need to be rebuilt from scratch; if transitory, Q2 2026 becomes the most important single quarter in the company's history (as of Q1 2026 filings).
• Question: What is the current FDA status of compounded semaglutide's shortage designation, and has HIMS received any informal guidance on the timeline for potential re-scheduling? Why it matters: An estimated $700-820M of FY25 revenue (est.) is tied to the compounding window; its closure would require a complete growth model rebuild and could trigger debt covenant issues given the leverage level.
• Question: What specific evidence did HIMS present to the FTC during its investigation, and what is the legal basis for its characterization that the FTC "disregards substantial evidence"?^[S13] Why it matters: If HIMS has genuinely strong legal defenses around its data-sharing practices (e.g., contractual consents, technical anonymization), the litigation risk is overpriced in the current multiple. If the defenses are weak, downside is substantially larger than the bear case implies.
• Question: How is HIMS servicing the $1.12B in debt raised in FY25 — what are the interest rate terms, maturity schedule, and covenant structure? Why it matters: At current TTM OCF of approximately $280M, interest coverage is adequate at most leverage ratios — but any covenant tied to EBITDA or operating income could be in technical breach given the Q1 2026 results.
• Question: What is the Q2 2026 revenue and margin guidance mgmt provided on the August 10 earnings call, and does it validate the FY26E consensus of $3.0B? (as of August 2026, earnings not yet reported) Why it matters: This is the single most important near-term catalyst; a raise on revenue guidance with margin recovery commentary would likely re-rate the stock 15-25% in a single session.
• Question: Argus Research cut its HIMS price target three times in approximately two weeks — from $37 to $34 to $28 — between July 15 and July 29, 2026.^{[S14][S16][S19]} What model changes drove each successive cut, and has any other firm followed with downgrades? Why it matters: Cascading analyst downgrades can create negative momentum that pressures the stock below fundamental value — or conversely, if the Street holds at HOLD, the 13-analyst consensus target of $29.23 provides a near-term floor.
• Question: What is the composition of the $1.38B increase in total liabilities in FY25 beyond the $1.12B debt raise — specifically, is there significant deferred revenue, customer deposits, or other non-debt liabilities embedded? Why it matters: If a significant portion of liabilities represents deferred revenue (a future revenue tailwind) rather than financial obligations, the balance sheet risk is being overestimated in the current narrative.
• Question: What is the update on HIMS's international expansion efforts and any new product category launches outside GLP-1 — particularly in mental health and women's health specialty care? Why it matters: Diversification away from GLP-1 compounding is the medium-term de-risking strategy; evidence of accelerating growth in non-GLP-1 categories would provide a hedge against regulatory binary risk and change the revenue quality narrative.

Disclaimer: This report is produced by Basis Report Research for informational and educational purposes only. It does not constitute investment advice, a solicitation, or an offer to buy or sell any security. The views expressed are those of the analyst and are based on publicly available information believed to be reliable but not guaranteed. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Basis Report Research and its affiliates may hold positions in securities discussed in this report.

11 Sources & Data As Of

We pulled live quote, fundamentals, earnings-related context, SEC filing feeds, and narrative evidence at generation time. High-impact claims should be tied to Tier 1 sources where available.

Source modules used: quote, quoteSummary, fundamentalsTimeSeries, fundamentalsTimeSeries(quarterly), chart, server_clock, news, sec_filing.

Report Data Retrieval Timestamp: Aug 1, 2026, 9:24 AM